Moreover, prior studies have demonstrated that inhibitors of BET, CDK1, HDAC, Protease, PI3K, and VEGFR could all decrease BRCA1 and other HRR factors at the protein level, thereby increasing the sensitivity of the cancer cell lines to PARP inhibition44–49. The gene discussed is CDK1; the disease is cancer.